You are here

Our science / Clinical Trials / Find a Trial / NCT01217918

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Back to Search Print Save as PDF Bookmark Trial

NCT01217918

Last updated on May 9, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Culver City, California, 90232 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy Volunteers

- Japanese

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with clinically significant skin lesions

- Subjects with known tuberculosis infection

NCT01217918
Pfizer
Completed
Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Healthy Volunteers
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
NCT03184168
Males
18+
Years
Madison, Wisconsin
Healthy Volunteers
A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin
NCT03386279
All Genders
18+
Years
Brussels,
Healthy
Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects
NCT03448172
Males
18+
Years
Multiple Sites
Healthy
Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects
NCT03534648
All Genders
18+
Years
Brussels,
Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects
APhase 1, Placebo-Controlled, Randomized, Parallel Group, Subject- And Investigator-Blind, Sponsor-Open Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PH-797804 Following Multiple Escalating Oral Doses In Healthy Japanese Adult Subjects
Study A6631027 will evaluate the safety, tolerability and pharmacokinetics of PH-797804 when administered to healthy Japanese subjects once a day (QD) for 10 days.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Healthy
  • Drug: 1 mg
    1 mg or placebo a material sparing tablet per day for 10 days
  • Drug: 5 mg
    5 mg or placebo as material sparing tablet per day for 10 days
  • Drug: 10 mg
    10 mg or placebo as a material sparing tablet per day for 10 days
  • Experimental: Cohort 1
    PH-797804
    Intervention: Drug: 1 mg
  • Experimental: Cohort 2
    PH-797804
    Intervention: Drug: 5 mg
  • Experimental: Cohotr 3
    PH-797804
    Intervention: Drug: 10 mg
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
February 2011
February 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy Volunteers
  • Japanese

Exclusion Criteria:

  • Subjects with clinically significant skin lesions
  • Subjects with known tuberculosis infection
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01217918
A6631027
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now